C2N Diagnostics LLC (C2N Diagnostics) is a diagnostics company that develops and commercializes novel diagnostics for alzheimer’s disease and neurological diseases, including memory disorders. The company offers products such as blood test kit for the treatment of alzheimer’s disease and dementia. It also provides bioanalytical services including sensitive mass spectrometry-based identification, quantification, and monitoring of proteins, protein fragments (peptides), and other biomolecules. The company markets its products under the Precivity, PrecivityAD2, PrecivityAD, and Precivity-ApoE brand names. C2N Diagnostics is headquartered in St. Louis, Missouri, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company C2N Diagnostics LLC
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- C2N Diagnostics LLC Company Overview
- C2N Diagnostics LLC Company Snapshot
- C2N Diagnostics LLC Pipeline Products and Ongoing Clinical Trials Overview
- C2N Diagnostics LLC - Pipeline Analysis Overview
- C2N Diagnostics LLC - Key Facts
- C2N Diagnostics LLC - Major Products and Services
- C2N Diagnostics LLC Pipeline Products by Development Stage
- C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
- C2N Diagnostics LLC Pipeline Products Overview
- Blood Test - Alzheimer’s Disease
- Blood Test - Alzheimer’s Disease Product Overview
- Diagnostic Test - Alzheimer's Disease
- Diagnostic Test - Alzheimer's Disease Product Overview
- Diagnostic Test - Brain Disease
- Diagnostic Test - Brain Disease Product Overview
- Diagnostic Test - Neurological Disease
- Diagnostic Test - Neurological Disease Product Overview
- eMTBR-tau243 Plasma Assay
- eMTBR-tau243 Plasma Assay Product Overview
- p-tau MAA
- p-tau MAA Product Overview
- p-tau217 Blood Test
- p-tau217 Blood Test Product Overview
- p-tau217 Blood Test Clinical Trial
- PrecivityAD2 Blood Test
- PrecivityAD2 Blood Test Product Overview
- PrecivityAD2 Blood Test Clinical Trial
- C2N Diagnostics LLC - Key Competitors
- C2N Diagnostics LLC - Key Employees
- C2N Diagnostics LLC - Locations And Subsidiaries
- Head Office
- Recent Developments
- C2N Diagnostics LLC, Recent Developments
- Mar 19, 2026: C2N Diagnostics Highlights First Use of Its eMTBR-tau243 Plasma Assay in Evoke/Evoke+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic Alzheimer’s Disease
- Mar 10, 2026: Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2 Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer’s Disease Diagnostics
- Feb 23, 2026: WashU Medicine introduces new blood test for Alzheimer’s symptom timing
- Nov 24, 2025: C2N Diagnostics Awarded Rigorous New York State Department of Health Permit, Expanding Ability to Provide Its Blood Tests to Help Diagnose Alzheimer’s Disease
- Nov 13, 2025: C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization
- Oct 01, 2025: Submission of C2N Diagnostics’ PRECIVITYAD2 Blood Test for FDA Review Underscores Continued Momentum Toward Precision Medicine
- Oct 01, 2025: C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test
- Sep 25, 2025: New Research Reinforces C2N’s PrecivityAD2 Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients
- Sep 10, 2025: UK Trial Launches to Transform Alzheimer’s Diagnosis With Simple Blood Test
- Sep 03, 2025: Dynamic Growth Leads C2N Diagnostics to Expand St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- C2N Diagnostics LLC Pipeline Products and Ongoing Clinical Trials Overview
- C2N Diagnostics LLC Pipeline Products by Indication
- C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
- C2N Diagnostics LLC, Key Facts
- C2N Diagnostics LLC, Major Products and Services
- C2N Diagnostics LLC Number of Pipeline Products by Development Stage
- C2N Diagnostics LLC Pipeline Products Summary by Development Stage
- C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
- C2N Diagnostics LLC Ongoing Clinical Trials Summary
- Blood Test - Alzheimer’s Disease - Product Status
- Blood Test - Alzheimer’s Disease - Product Description
- Diagnostic Test - Alzheimer's Disease - Product Status
- Diagnostic Test - Alzheimer's Disease - Product Description
- Diagnostic Test - Brain Disease - Product Status
- Diagnostic Test - Brain Disease - Product Description
- Diagnostic Test - Neurological Disease - Product Status
- Diagnostic Test - Neurological Disease - Product Description
- eMTBR-tau243 Plasma Assay - Product Status
- eMTBR-tau243 Plasma Assay - Product Description
- p-tau MAA - Product Status
- p-tau MAA - Product Description
- p-tau217 Blood Test - Product Status
- p-tau217 Blood Test - Product Description
- p-tau217 Blood Test - The Swedish BioFINDER - Memory Clinic Study
- p-tau217 Blood Test - The Swedish Biofinder 2 Study
- PrecivityAD2 Blood Test - Product Status
- PrecivityAD2 Blood Test - Product Description
- PrecivityAD2 Blood Test - Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
- C2N Diagnostics LLC, Key Employees
- Glossary
- C2N Diagnostics LLC Pipeline Products by Equipment Type
- C2N Diagnostics LLC Pipeline Products by Development Stage
- C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acelot Inc
- 4M Therapeutics Inc
- Accuitis Inc
